Twitter | Pretraživanje | |
Pretraživanje Osvježi
Cytonus Therapeutics 1 h
You can find our CEO next week presenting our next-generation cell-therapy in NYC. &Families Cytonus Therapeutics Selected to Present at BIO CEO & Investor Conference in New York City via
Reply Retweet Označi sa "sviđa mi se"
ASGCT 6 h
Did you know there are more than 400 active and recruiting clinical trials in and across the U.S.? You can search them using our Clinical Trials Finder, which is updated daily.
Reply Retweet Označi sa "sviđa mi se"
Big4Bio:SFBay 6 h
Listen to Nkarta Therapeutics' CSO James Trager talk about the company's platform on February 18, 2020.
Reply Retweet Označi sa "sviđa mi se"
USC Stem Cell 8 h
Great lecture by Dr. Clive Svendsen to our Master Program course SCRM 515: Bring Stem Cells to the Clinics. He walked through his journey of developing gene therapy for Parkinson's Disease and cell and gene therapy for ALS. Great work!
Reply Retweet Označi sa "sviđa mi se"
S.C. Yatta 10 h
There will be a time when you just have to take a deep breath, relax, and let things go. Focus on what and who really matters to you and the rest will work itself out... I Am S.C. Yatta Follow me on Facebook Instagram and Twitter @ S.C. Yatta
Reply Retweet Označi sa "sviđa mi se"
Single Use Support 15 h
4 hacks that allow you to push patient safety during cell and gene therapies to the next level. Check out our – our logistical solution for a successful CAR-T cell therapy!  _________
Reply Retweet Označi sa "sviđa mi se"
MaxVal 16 h
Take a look at our insights covering the novel treatment approaches and advancements in CAR-T cell therapies. -T
Reply Retweet Označi sa "sviđa mi se"
Comprehensive Cell Solutions @CCSNYBC 18 h
PACT Pharma strives to expand their manufacturing operations of products, raising $75 million in their Series C financing round. Read about how they plan to develop new cell therapies that target solid tumors ==>
Reply Retweet Označi sa "sviđa mi se"
RoslinCT 19 h
[Infographic] We can’t believe that the first month of 2020 is already over! Reflecting back, 2019 was a great year for RoslinCT. Looking ahead, 2020 is already gearing up to be even better!
Reply Retweet Označi sa "sviđa mi se"
Jesus del Valle 22 h
Reply Retweet Označi sa "sviđa mi se"
Tmunity Therapeutics 5. velj
Tmunity is committed to our relentless pursuit of restoring hope for cancer patients worldwide
Reply Retweet Označi sa "sviđa mi se"
Genetic Engineering & Biotechnology News 4. velj
With $315M acquisition, eyes growth in development, manufacturing:
Reply Retweet Označi sa "sviđa mi se"
Leah Kesselman, CellCAN 4. velj
These talks have been broken up into bite-sized pieces - if you have 15-30 minutes, you can watch one of these webinars from our wonderful supply chain and logistics speakers!
Reply Retweet Označi sa "sviđa mi se"
Birmingham Health Partners 4. velj
Rewinding to a great news story on - Sophie, the first person in the Midlands to receive advanced CAR-T , is now in complete remission from leukaemia as a result of this advanced treatment >
Reply Retweet Označi sa "sviđa mi se"
S.C. Yatta 3. velj
Worrying doesn’t change your situation focus your energy on the outcome you want then do what you can to make it happen.. I Am S.C. Yatta Follow me on Facebook Instagram and Twitter @ S.C. Yatta
Reply Retweet Označi sa "sviđa mi se"
Catalent Pharma 3. velj
Catalent To Acquire Leading Cell Therapy Company MaSTherCell Global for $315 Million, Creating an Industry-Leading Cell & Gene Therapy Platform Read more:
Reply Retweet Označi sa "sviđa mi se"
Image Box LS PR 3. velj
Orgenesis sells Masthercell Global, its contract development and manufacturing organisation subsidiary. Will use $127 million to continue to grow its point-of-care business and to further the development of its .
Reply Retweet Označi sa "sviđa mi se"
Frontage Labs 3. velj
Register for our exclusive Bioanalysis Zone Coffee Chat focusing on developments in cell and gene therapies featuring Frontage's expert, Weiping Shao! Register, here:
Reply Retweet Označi sa "sviđa mi se"
Lineage Cell Therapeutics 30. sij
Lineage is developing a novel to treat dry age-related macular degeneration (), the leading cause of irreversible vision loss in the US. OpRegen is currently in Phase I/IIa and has the potential to help many patients.
Reply Retweet Označi sa "sviđa mi se"
Shomail's 30. sij
Love the fresh clod weather and view..
Reply Retweet Označi sa "sviđa mi se"